Dr. Rosenberg Discusses the Importance of Clinical Trials in Bladder Cancer

Video

In Partnership With:

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of referring patients to clinical trials in bladder cancer.

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of referring patients to clinical trials in bladder cancer.

There is a long history of failed adjuvant clinical trials in bladder cancer due to poor accrual, says Rosenberg. He says that is important for treating physicians to recommend patients for these trials in order to test novel adjuvant therapies.

Adjuvant immunotherapy trials are showing greater success in accrual though, Rosenberg adds.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
Elias Jabbour, MD